Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Myriad Genetics Stock Gained as Much as 14.1% Today

By Maxx Chatsko - Aug 22, 2018 at 3:28PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The genetic testing leader announced fiscal fourth-quarter 2018 earnings results and gave guidance for next year. It's the news shareholders have been waiting for.

What happened

Shares of Myriad Genetics (MYGN -0.42%) rose over 14% today after the genetic testing pioneer announced fiscal fourth-quarter and full-year 2018 results. The business delivered a 31% year-over-year increase in adjusted EPS for the final three months of its fiscal year. The recent strength is just the latest indicator that the transition to a broader portfolio of products is proving to be a success. 

That's important, considering Myriad Genetics was almost entirely dependent on its breast cancer diagnostics in the past. Those products quickly became a target of lower-cost competition, and the company's first new products got off to slow starts in fiscal 2016 and fiscal 2017. But they exited fiscal 2018 with the wind at their backs.

As of 2:59 p.m. EDT, the stock had settled to a 9.8% gain.

A white-gloved hand holding up a silver platter with a piece of DNA on it.

Image source: Getty Images.

So what

In fiscal 2018, hereditary cancer testing products accounted for 69% of total revenue, compared to 79% of total revenue in the previous year. The difference of $69 million was made up almost dollar-for-dollar by growth platforms GeneSight, Vectra DA, Prolaris, and EndoPredict -- each of which grew year-over-year revenue by double digits. Even with that, Myriad Genetics reported total revenue of $719 million for the full year, which was nearly identical to the year-ago total.

The stagnation on the top line was more than offset by a steep reduction in operating expenses, which resulted in fiscal full-year 2018 operating income of $119 million, an increase of 144% compared to the prior year. Net income saw a year-over-year increase of 539%.

GeneSight, the most important growth platform, grew 59% year over year and accounted for 17% of total revenue, up from just 11% in fiscal 2017. Meanwhile, Myriad Genetics closed the acquisition of reproductive genetic testing leader Counsyl on the last day of July, which will provide an important new growth opportunity. The company estimates reproductive genetic testing markets will reach $1.5 billion in annual revenue within the next five years. Both will prove key to pushing the company back to top-line growth in fiscal 2019.

Now what

The effort to diversify the business away from legacy hereditary cancer testing products is working, but so far the newer platforms have only replaced lost revenue. That's about to change. Myriad Genetics issued its first fiscal 2019 financial guidance, which calls for up to $890 million in revenue along with up to $1.75 in adjusted EPS. That would mark year-over-year growth of 24% and 70%, respectively. Simply put, it looks like shareholders will be rewarded for their patience during the last few years.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Myriad Genetics, Inc. Stock Quote
Myriad Genetics, Inc.
$21.26 (-0.42%) $0.09

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.